Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 9;7(7):545.
doi: 10.3390/jof7070545.

Risk Factors for Fungal Co-Infections in Critically Ill COVID-19 Patients, with a Focus on Immunosuppressants

Affiliations
Review

Risk Factors for Fungal Co-Infections in Critically Ill COVID-19 Patients, with a Focus on Immunosuppressants

Obinna T Ezeokoli et al. J Fungi (Basel). .

Abstract

Severe cases of coronavirus disease 2019 (COVID-19) managed in the intensive care unit are prone to complications, including secondary infections with opportunistic fungal pathogens. Systemic fungal co-infections in hospitalized COVID-19 patients may exacerbate COVID-19 disease severity, hamper treatment effectiveness and increase mortality. Here, we reiterate the role of fungal co-infections in exacerbating COVID-19 disease severity as well as highlight emerging trends related to fungal disease burden in COVID-19 patients. Furthermore, we provide perspectives on the risk factors for fungal co-infections in hospitalized COVID-19 patients and highlight the potential role of prolonged immunomodulatory treatments in driving fungal co-infections, including COVID-19-associated pulmonary aspergillosis (CAPA), COVID-19-associated candidiasis (CAC) and mucormycosis. We reiterate the need for early diagnosis of suspected COVID-19-associated systemic mycoses in the hospital setting.

Keywords: COVID-19; COVID-19-associated candidiasis; COVID-19-associated pulmonary aspergillosis; corticosteroid treatment; fungal co-infections; mucormycosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Distribution (a) and co-occurrence (b) of fungal species across randomly selected 50 case studies, prospective and retrospective published reports on fungal co-infections in hospitalized COVID-19 patients [5,7,9,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56] (also see Supplementary Table S1). Searches were done on PubMed (Medline) and Google Scholar using query terms such as “Co-infections”, “coinfections”, “fungi” or “Fungal infections” in combination with either “COVID-19” or “SARS-CoV-2”. Most (>50%) of the selected articles included cases from the onset of the COVID-19 pandemic in several countries (December 2019–April 2020). In the co-occurrence network, nodes are colored based on betweenness centrality (species with high co-occurrence), while edges (connecting lines) indicate significant (p < 0.05) co-occurrence between species. The network was constructed using the visNetwork package of R (https://cran.r-project.org/web/packages/visNetwork/index.html, accessed on 21 May 2021) and further annotated in Gephi (https://gephi.org/, accessed on 21 May 2021).

References

    1. Worldometers COVID Live Update. [(accessed on 23 June 2021)]; Available online: https://www.worldometers.info/coronavirus/
    1. WHO Coronavirus Disease (COVID-19) [(accessed on 21 May 2021)]; Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    1. Ezeokoli O.T., Pohl C.H. Opportunistic pathogenic fungal co-infections are prevalent in critically ill COVID-19 patients: Are they risk factors for disease severity? S. Afr. Med. J. 2020;110:1081–1085. doi: 10.7196/SAMJ.2020.v110i11.15248. - DOI - PubMed
    1. Song G., Liang G., Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia. 2020;185:599–606. doi: 10.1007/s11046-020-00462-9. - DOI - PMC - PubMed
    1. Salmanton-García J., Sprute R., Stemler J., Bartoletti M., Dupont D., Valerio M., Garcia-Vidal C., Falces-Romero I., Machado M., de la Villa S., et al. COVID-19-associated pulmonary aspergillosis, March–August 2020. Emerg. Infect. Dis. 2021;27:1077–1086. doi: 10.3201/eid2704.204895. - DOI - PMC - PubMed

LinkOut - more resources